Efavirenz: enhancing the gold standard

Int J STD AIDS. 2003 Oct:14 Suppl 1:6-14. doi: 10.1258/095646203322491824.

Abstract

Efavirenz, the potent, once-daily non-nucleoside reverse transcriptase inhibitor, has been successfully used since 1996 and is still a cornerstone of antiretroviral therapy for use in treatment-naïve, treatment-experienced and difficult-to-treat patients. The efficacy of efavirenz in these patient groups has been established in many clinical and cohort studies. Furthermore, efavirenz is now available as a single 600 mg tablet, providing a simplified therapy and decreased pill burden, which may lead to improved adherence and treatment outcomes. Efavirenz has a well-characterized tolerability profile, the more notable side effects being mainly short-term and non-life-threatening, such as central nervous system disturbances and rash.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Alkynes
  • Anti-HIV Agents / adverse effects
  • Anti-HIV Agents / therapeutic use*
  • Benzoxazines
  • Central Nervous System Diseases / chemically induced
  • Cyclopropanes
  • Drug Administration Schedule
  • HIV Infections / drug therapy*
  • Humans
  • Oxazines / adverse effects
  • Oxazines / therapeutic use*
  • Patient Compliance

Substances

  • Alkynes
  • Anti-HIV Agents
  • Benzoxazines
  • Cyclopropanes
  • Oxazines
  • efavirenz